Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

ATTAIN-J Orforglipron Trial Results

ATTAIN-J found greater weight loss with oral orforglipron than placebo in Japanese adults, with gastrointestinal tolerability limits.

Why we wrote this. The fetched brief mislabeled a nonpeptide GLP-1 drug as tirzepatide. The trial deserves a readout without the false taxonomy link.

In this article (5 sections)
  1. How ATTAIN-J was designed
  2. What the weight outcomes showed
  3. Adverse events and discontinuation
  4. What the trial does not establish
  5. Bottom line

ATTAIN-J found that once-daily oral orforglipron reduced average body weight more than placebo over 72 weeks in Japanese adults with obesity disease. Mean changes were -5.9% with 6 mg, -8.7% with 12 mg, and -7.9% with 36 mg, compared with -0.6% with placebo. All three comparisons met the trial's statistical threshold[1]. The 12 mg group had the largest average reduction, so the findings do not show a simple pattern in which the highest studied dose produced the greatest weight change.

Orforglipron is a small-molecule, nonpeptide oral GLP-1 receptor agonist. It should not be classified as a peptide or grouped under the tirzepatide peptide taxonomy. Readers can use our tirzepatide evidence page and semaglutide evidence page for separate drug-specific evidence, but ATTAIN-J did not compare orforglipron with either medicine[1].

How ATTAIN-J was designed

ATTAIN-J was a phase 3, randomized, double-blind, placebo-controlled trial at 16 research centres and hospitals in Japan. It enrolled 238 adults. Participants had a body mass index from 27 to below 35 with at least two obesity-related health disorders, or a body mass index of 35 or higher with at least one such disorder. At least one qualifying disorder had to be hypertension, dyslipidaemia, or type 2 diabetes. About one quarter of the sample was intended to have type 2 diabetes[1].

Participants were assigned to oral orforglipron 6 mg, 12 mg, or 36 mg, or placebo, once daily. The registry shows that active-treatment groups began at 1 mg and increased every four weeks to their assigned target. Treatment accompanied a reduced-calorie diet and increased physical activity. These are protocol details, not instructions for personal use[2]. The co-primary outcomes were percentage change in body weight and the percentage of participants losing at least 5% of baseline weight at week 72.

The 238 randomized participants had a mean age of 54.1 years, and 61% were men. Group sizes ranged from 57 to 61. A total of 214 participants, or 90%, completed the study[1]. ClinicalTrials.gov marks the study completed and has posted results, including the primary outcomes and adverse-event tables[2].

What the weight outcomes showed

At least 5% weight loss was estimated in 45.6% of participants assigned 6 mg, 60.8% assigned 12 mg, and 58.8% assigned 36 mg, compared with 15.2% assigned placebo. Each orforglipron group differed statistically from placebo[1]. The registry's posted analysis reports closely aligned model-based estimates, which provides official corroboration for the direction and size of the primary findings[2].

Those percentages are group averages from a defined trial population. They do not predict one person's result, and they do not establish that 12 mg is generally preferable to 36 mg. Differences between dose groups were not the article's stated primary comparison. The primary tests compared each active group with placebo. Reading the 12 mg and 36 mg point estimates as a proven head-to-head ranking would go beyond that design.

The trial also used a treatment-regimen estimand for efficacy, a statistical approach intended to estimate outcomes while accounting for what happened after randomization under the specified analysis plan. That matters because missing measurements and use of other weight-management treatment can affect a week-72 estimate. The headline result is not simply the average among people who stayed on treatment and had a final measurement.

Adverse events and discontinuation

The publication describes adverse events with orforglipron as mostly mild-to-moderate gastrointestinal symptoms. Nausea led to treatment discontinuation in one participant in each of the 6 mg and 12 mg groups and five participants in the 36 mg group. Vomiting led to discontinuation in none, two, and one participant, respectively. Neither event caused a discontinuation in the placebo group[1].

The registry reports serious adverse events in 5 of 60 placebo participants, 1 of 61 in the 6 mg group, 3 of 57 in the 12 mg group, and 6 of 60 in the 36 mg group. It also records one death in the 36 mg group and none in the other groups[2]. Those counts should not be used to infer causation from this small trial. Event-level assessment, investigator attribution, timing, and the full clinical record are needed before linking an isolated event to treatment.

The pattern of nausea-related discontinuation is relevant because the highest-dose group had more withdrawals for that reason while not showing the largest average weight reduction. Still, ATTAIN-J was not large enough to define uncommon risks. A 238-person study can describe common tolerability findings better than rare or delayed harms.

What the trial does not establish

ATTAIN-J answers a narrow question about placebo-controlled efficacy and safety in Japanese adults who met specific obesity-disease criteria. It does not compare orforglipron directly with semaglutide, tirzepatide, surgery, or another active obesity treatment. It also cannot show that its averages apply unchanged to populations with different body-size distributions, comorbidities, care settings, or background treatment.

Eli Lilly funded the trial. Several authors were Lilly employees and shareholders, and other authors disclosed financial relationships with multiple pharmaceutical companies[1]. Sponsor funding does not invalidate a randomized study, but it makes transparent protocol registration, posted results, conflict disclosures, and independent scrutiny especially important. The registry and journal abstract agree on the core design and primary result.

Longer and larger studies are needed to characterize rare adverse events, durability after treatment ends, and clinical outcomes beyond weight and cardiometabolic markers. This single trial also does not settle how an oral small-molecule GLP-1 receptor agonist compares with injectable peptide medicines. Chemistry, delivery, efficacy, safety, availability, and regulatory status are separate questions.

Bottom line

ATTAIN-J provides peer-reviewed phase 3 evidence that orforglipron produced greater average weight loss than placebo at all three studied target doses over 72 weeks in this Japanese population. The 12 mg group had the largest average change, and gastrointestinal symptoms were the main tolerability issue described in the publication. The result supports further evaluation of orforglipron as an oral nonpeptide GLP-1 receptor agonist. It does not support relabelling it as a peptide, claiming superiority to another medicine, or choosing a dose without clinical guidance.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

What is orforglipron?

Orforglipron is a small-molecule, nonpeptide oral GLP-1 receptor agonist. It is not a peptide and should not be assigned to tirzepatide or another peptide taxonomy solely because it acts at the GLP-1 receptor.

How much weight did participants lose in ATTAIN-J?

At week 72, mean body-weight changes were -5.9% with orforglipron 6 mg, -8.7% with 12 mg, and -7.9% with 36 mg, compared with -0.6% with placebo.

Did ATTAIN-J compare orforglipron with tirzepatide or semaglutide?

No. ATTAIN-J compared three orforglipron target doses with placebo. It did not include tirzepatide, semaglutide, or another active obesity medicine as a comparator.

What were the main side effects in ATTAIN-J?

The publication describes mostly mild-to-moderate gastrointestinal symptoms. Nausea and vomiting were the treatment-emergent adverse events that most often led participants to discontinue study treatment.

Sources

  1. [1]Yokote K et al. Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J). Lancet Diabetes & Endocrinology. 2026. PMID 42962687.Tier 1 · primary↩
  2. [2]ClinicalTrials.gov: ATTAIN-J phase 3 trial and posted results, NCT05931380Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.